*Bvf INC Holds Stake in Chemocentryx INC (CCXI)

June 27, 2018 - By Sarah Holford

ChemoCentryx, Inc. (NASDAQ:CCXI) Corporate LogoBig Money Sentiment decreased to 1 in 2018 Q1. It has change of 0.30, from 2017Q4’s 1.3. The ratio dived due to CCXI positioning: 10 sold and 36 reduced. 24 funds acquired holdings and 22 increased holdings. Investors holded 23.51 million in 2017Q4 but now own 24.22 million shares or 3.03% more. Trexquant Invest Lp invested 0.01% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Citigroup Incorporated has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Rhumbline Advisers reported 23,578 shs. Moreover, Amer Interest Gp Incorporated has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 15,795 shs. Connor Clark And Lunn Invest Management holds 0% or 56,739 shs in its capital. Panagora Asset Mgmt has invested 0.02% in ChemoCentryx, Inc. (NASDAQ:CCXI). The New York-based Jpmorgan Chase has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Credit Suisse Ag, Switzerland-based fund reported 13,269 shs. Td Asset reported 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein Lp holds 40,100 shs or 0% of its capital. Baker Bros Ltd Partnership holds 414,029 shs. Pnc Financial Grp Incorporated Inc accumulated 219,821 shs. Schwab Charles Investment owns 43,100 shs. Federated Invsts Inc Pa has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Blackrock has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

CCXI had 8 sales and 0 insider purchases since May 1, 2018. This’s net activity of $6.04 million. On Wednesday, May 2 KANAYA SUSAN M also sold $15,709 worth of ChemoCentryx, Inc. (NASDAQ:CCXI). Another trade for 50,000 shs valued at $590,637 was made by Cappel Markus J. on Wednesday, May 16.

According to 2018Q1 Securities and Exchange filling the Bvf Inc decreased its holdings in Chemocentryx Inc (CCXI) by 5.09%. The company’s stock rose 32.26% while stock markets declined as Bvf Inc sold 386,100 shares. At the end of 2018Q1, the hedge fund held 7.20M shares of the health care company, valued at $97.94 million, down from 7.59M at the end of the previous reported quarter. For a total of 4.11 million shares it increased its holding in Immune Design Corp (NASDAQ:IMDZ) by 2.64M shares in the quarter, and has risen its stake in Pieris Pharmaceuticals Inc.

ChemoCentryx, Inc. (NASDAQ:CCXI) is expected to announce earnings on August, 14., according to Zacks. Analysts expect change of 31.58 % or $0.06 from previous year’s $-0.19 earnings per share compared to current’s $-0.25 earnings per share. Last quarter $-0.19 earnings per share was reported. Analysts forecasts 31.58 % negative EPS growth this quarter.

Another two news for ChemoCentryx, Inc. (NASDAQ:CCXI) were recently published by: Globenewswire.com on May 30, 2018 with title “ChemoCentryx to Present at Two Upcoming Investor Conferences”. The other Finance.Yahoo.com‘s article was titled “4 Top-Ranked Nasdaq Stocks That Have Doubled This Year” and published on June 14, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

In total 3 analysts cover ChemoCentryx (NASDAQ:CCXI). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CCXI) has 100% bullish analysts. With $20 highest and $16 lowest target, ChemoCentryx has $17.67 average target or 35.20% above the current ($13.07) price. 3 are the (NASDAQ:CCXI)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Tuesday, March 13 the company was maintained by JP Morgan.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.